While emollients remain the cornerstone of AD management, the systemic treatment paradigm has evolved significantly in recent years, transitioning from conventional immunosuppressants to targeted biologics (e.g., IL-4/IL-13 inhibitors) [4,5] and, more recently, small-molecule therapies (e.g., JAK inhibitors) [6]. Here, IL13 is linked to Alzheimer disease.